Merck & Co. has announced promising results from the third phase 3 trial of its PCSK9 inhibitor, enlicitide, which demonstrates significant advantages over existing oral non-statin therapies for cardiovascular disease. The Coralreef AddOn study, presented at the American College of Cardiology’s annual meeting, revealed that enlicitide led to an impressive average reduction of 64.6% in LDL cholesterol among statin-treated adults with atherosclerotic cardiovascular disease, outpacing control treatments that included bempedoic acid and ezetimibe.

The implications of these findings are substantial for the longevity and healthspan sectors, particularly in the context of cardiovascular health, which is a critical factor in aging populations. Enlicitide not only achieved primary endpoints but also surpassed secondary measures, including a 54.6% reduction in apolipoprotein B and a 58.0% decrease in non-HDL cholesterol. These results suggest that enlicitide could become a vital therapeutic option for patients requiring enhanced LDL-C reduction, potentially reshaping treatment paradigms in cardiovascular care.

One key takeaway from Merck’s announcement is the anticipated timeline for FDA approval, with hopes for an expedited market entry due to a National Priority Voucher. If successful, enlicitide could be available as early as 2027, providing a new tool for clinicians focused on mitigating cardiovascular risk in aging populations. This development not only highlights the ongoing innovation in lipid-lowering therapies but also underscores the importance of addressing cardiovascular health as a component of longevity research and healthspan enhancement.

Source: fiercebiotech.com